A rare type of antibody that spontaneously binds to each self (homodimerizes) has been described. This self-binding (autophilic) antibody provides stronger protection against bacterial infection than a non self-binding antibody with identical specificity and affinity due to increase of polymeric avidity. A peptide derived from the self-binding domain of the autophilic antibody was crosslinked to the Fc carbohydrate of two monoclonal antibodies specific for the B-cell receptor (BCR) of a murine and a human B-cell tumor. Peptide-crosslinked antibodies bind to themselves on solid phase ELISA as homodimer and establish in solution a monomer-dimer equilibrium. Autophilic antibodies bind to their respective tumor target cells with increased efficiency as determined by FACS analysis. They also induce twice the amount of apoptosis of target tumor cells than the control antibodies. Furthermore, the modified antibodies inhibit tumor growth in culture more efficiently than the control antibodies. Criss-cross protocols in FACS, apoptosis, and growth inhibition indicate the specificity of targeting the BCR with autophilic antitumor antibodies. The chemical approach of increasing the binding of antibodies without creating chemically crosslinked dimers mimics naturally occurring autophilic antibodies and represents a simple and attractive alternative to chemical dimerizing and antibody engineering techniques for improving their antitumor effect. Furthermore, these results provide a guide to incorporate the self-binding peptide into the structure of antibodies using modeling and molecular crafting techniques.
Antibodies, being a major arm of adaptive immunity, improve their targeting ability after antigen challenge through mechanisms of somatic mutation and receptor editing in concert with clonal selection. These mechanisms require the help of T-cells that recognize peptides derived from protein antigens. For nonprotein antigens, such as carbohydrates, these mechanisms are not available, because T cells typically do not recognize carbohydrate. Thus, antibodies against carbohydrate antigens are mostly of the IgM class with close resemblance to the germline gene structure. The polymeric structure of IgM, providing the benefit of subunit mediated increase in avidity, compensates for the lack of T-cell dependent affinity maturation. The avidity bonus from covalent antibody polymerization can also be obtained through noncovalent intermolecular homophilic interactions via (i) the Fc-Fc mediated dimerization in mouse IgG3 class antibodies (1) and (ii) the Fab-Fab mediated self-binding of autophilic antibodies (2, 3) .
The self-binding property of antibodies was discovered in a group of mouse antibodies that form soluble self-complexes without chemical bonds (2) . Subsequently, we described a peptide region in the variable domain of a self-binding antibody (autobody) that inhibits the self-aggregation (4) . The peptide is derived from the variable domain of the heavy chain and comprises regions of CDR2 and FR3 of the germline encoded S107/TEPC15 (T15) antibody. The autophilic site is present on antibodies with different specificity (5) rendering its expression independent of antigen driven selection. Because of the antigen-independent expression of the autophilic effect, we considered the possibility to attach the autophilic peptide to monomeric antibodies and to create polymeric antibodies with increased avidity. This hypothesis was tested by affinity crosslinking the autophilic T15 peptide to antibodies against the Bcell receptor (BCR) of lymphoma tumors.
The antitumor effect of antibodies against the BCR is mediated by negative signaling requiring crosslinking of the BCR (6) (7) (8) (9) . This signal for growth arrest and apoptosis (10, 11) of the B-cell tumor is greatly enhanced by homodimerizing antibodies that occur either spontaneously (12) or can be manufactured by chemical crosslinking (13) .
In a recent study (14) , we have generated an autophilic antibody against CD-20 of human B-cell lines and shown enhanced antitumor effects. Here we extended this approach using antibodies against the BCR molecule of a human and a murine B-cell line and demonstrate a monomer-dimer equilibrium of autophilic antibodies in solution that are not chemically crosslinked.
MATERIALS AND METHODS

Cell Line and Antibodies
The human B-cell tumor line (Su-DHL4) and murine B-cell tumor line (38C13) are grown in RPMI 1640 medium (supplemented with 10% fetal bovine serum, 2 mol/L glutamine, 10 mol/L HEPES, 50 U/mL penicillin, and 50 g/mL streptomycin, 50 mol/L 2-mercaptoethanol) at 37°C under 5% CO 2 . Two mAb 5D10 and S1C5, specific for the human or murine BCR, respectively, were used in this study. The antibodies are purified from the culture supernatant by protein G and protein A affinity chromatography.
Synthesis of Antibody-Peptide Conjugate
T15H peptide (ASRNKANDYTTDYSASVKGRFIVSR), a V H -derived peptide from a self-binding antibody-T15 (5), was synthesized by Genemed Synthesis (San Francisco, CA, U.S.A.). Antibodies were dialyzed against PBS (pH6.0) and 1/10 volume of 200 mol/L NaIO 4 was added and incubated at 4°C for 30 minutes in the dark. The reaction was stopped by adding glycerol to 30 mol/L, and the sample was dialyzed at 4°C for 30 minutes against PBS (pH 7.0). 100 times molecular excess of T15H or scrambled peptide was added to the antibodies and incubated at 37°C for 1 hour. L-Lysine was added and incubated at 37°C for 30 minutes to block the remained aldehyde group. The same oxidation reaction steps (except adding the peptides) were applied to antibodies used as controls. After the blocking step, the antibody-conjugates were dialyzed against PBS (pH 7.2) overnight.
Ig Capture ELISA
Four g/mL of S1C5-T15H was coated to Costar vinyl assay plates (Costar, Cambridge, MA, U.S.A.). After blocking with 3% BSA solution, 8 g/mL of photobiotinylated S1C5-T15H (15), S1C5-scrambled peptide conjugate, and control S1C5 were added to the first wells, and 1:1 dilution was performed. The antibodies were incubated for 2 hours at room temperature. After washing with PBS buffer, Avidin-HRP (Sigma, St. Louis, MO, U.S.A.) was added as a 1:2500 dilution. The binding antibodies were visualized by adding substrate ophenylenediamine.
Size Exclusion Chromatography
Antibody conjugate was chromatographed on a 75 mL Sephacryl 300HR column (Pharmacia, Peapack, NJ, U.S.A.). 1:10 diluted PBS (pH 7.2) was chosen as elution buffer. Fractions (0.5 mL/each) were collected and aliquots (100 L) were assayed on antihuman IgG capture ELISA. The ELISA reading (OD 490 nm) is plotted against elution volume.
Viability Assay for Antibody-Treated Cells
The lymphoma cells were grown in 96-well tissue culture wells in 1-mL medium. 2 g of antibodies or antibody-peptide conjugates were added and incubated for various times as described in the "RESULTS" section. Ten L aliquots from the cell suspension were used to determine viability by using trypan blue exclusion.
FACS Assay of the B-Cell Lymphoma
The Su-DHL4 and 38C13 cells were fixed with 1% paraformaldehyde. 1 × 10 6 cells were suspended in 50 L of staining buffer (Hank's balanced salt solution, containing 0.1% NaN 3 , 1.0% BSA), then 1.5 g of photobiotinylated S1C5-T15H conjugates (15) 
Hoechst-Merocyanin 540 Staining to
Detect Apoptosis 1 × 10 6 of lymphoma cells were placed into 24-well tissue culture wells. Four g of antibodies or antibodypeptide conjugates were added and incubated for various times as described in the "RESULTS" section. 1 × 10 6 cells were removed from the culture, resuspended in 900 L cold PBS (pH 7.2). One hundred L of Hoechst 33342 (50 g/mL; Molecular Probe, Eugene, OR, U.S.A.) was added, the cells were incubated at 37°C for 30 minutes in the dark. The cells were centrifuged and resuspended in 100 L PBS. Then, 4 L of MC540 solution (Molecular Probe) was added, and a 20-minute incubation was performed at room temperature in the dark. The cells were pelleted, resuspended in 1 mL cold PBS (pH 7.2), and analyzed by flow cytometry (16) .
RESULTS
Characterization of Autophilic Antibodies
The T15H (24-mer) peptide (4) was crosslinked to two murine mAb (S1C5 and 5D10), using carbohydrate periodate conjugation (17) . The mAb S1C5 (IgG1) is specific for the tumor idiotype of the mouse 38C13 B-cell line (18) and the 5D10 antibody for the human Su-DHL4 B-cell tumor (19) . Both antibodies recognize unique idiotypes of the BCR IgM on the B-cell tumors.
Self-Binding Behavior can Easily be Demonstrated by ELISA
The autophilic self-binding effect was studied with the T15H peptide-crosslinked mAb S1C15. As seen in Figure 1A (panel A), the T15H-crosslinked S1C5 binds to insolubilized S1C5-T15H detected by biotin-avidin ELISA. Control S1C5 does not bind significantly to S1C5-T15H or S1C5 crosslinked with a scrambled peptide. Similar self-binding of T15H peptide-crosslinked mAb 5D10 to insolubilized T15H-5D10 was also observed (Fig. 1A [panel B] ).
The specificity of the peptide mediated autophilic effect was tested using the 24 mer peptide T15H itself as an inhibitor. As seen in Figure 1B , only the T15H peptide inhibited S1C5-T15H (Fig. 1B [panel A] ) and 5D10-T15H (Fig. 1B [panel B] ) self-binding while the control scrambled peptide did not inhibit it. These results are similar to the previously published inhibition data with the naturally occurring autophilic T15/S107 antibody (4,5).
T15H-Antibody Conjugates Form an Equilibrium of Monomer and Dimer in Solution
The noncovalent nature of the self-aggregation of T15H-linked antibodies raises the question of its physical state in solution. To address this issue, we analyzed the molecular species of T15H-linked mAb using gel electrophoresis and sizing gel filtration. In Figure 1C , the electrophoretic mobility of control and T15H peptideconjugated S1C5 and 5D10 under reducing and nonreducing conditions show no differences, indicating the absence of chemical bonds between the antibody chains. The faint band in lanes 3 and 4 of Figure 1C represent dimers of T15H-linked mAb.
The molecular species of the peptide conjugated antibodies (5D10-T15H) was further analyzed by size exclusion chromatography. In Figure 2 , representative results are shown. The elution profile indicated two immunoglobulin species of different size ( Fig. 2A) . The second smaller peak eluted in the position of nonconjugated 5D10 antibody. The larger first peak eluted in the position of an antibody dimer. The appearance of two peaks resembled monomer and dimer antibodies and could indicate that either a fraction of antibodies was not modified to polymerize, or that the modification was complete and the antibody establishes an equilibrium of dimers and monomers. To test the latter possibility, material from both peaks were subjected to a second gel filtration on the same column. Reruns of both peaks yielded again two peaks (Figs. 2B and C) at the same position as in the first chromatography. The inserts in Figure 2 show the SDS-PAGE of the material from peak I and II, indicating the typical heavy (H) and light (L) chain bands of antibodies. These data show that the T15H peptide-linked antibodies exist in solution as two distinct molecular species that form an equilibrium of monomer and dimer. This behavior is reminiscent of the gel filtration data on the natural self-binding antibody T15 (20) .
Enhanced Binding of Autophilic Antibodies to Tumors
The binding of the peptide conjugated antibodies against their respective tumor targets was compared with that of the control antibodies in indirect fluorescence activated cell sorting (FACS). As control, antibodies linked with a scrambled peptide were included. In Figure  3A , the fluorescence intensity of the T15H-S1C5 on 38C13 cells (Fig. 3A [panel D] ) is compared with that by the control S1C5 (Fig. 3A [panel B] ) and the scrambled peptide S1C5 (Fig. 3A [panel C]) . The difference in mean fluorescence channels between S1C5-T15H and controls was greater than 1 log. Similarly, the FACS analysis of autophilic 5D10-T15H on Su-DHL4 cells shows enhancement of binding over binding of control 5D10 and control peptide-crosslinked 5D10 (Fig. 3A [panel D versus panels B and C]). In both tumor systems, the conjugation of the T15H peptide to tumor-specific antibody enhanced the FACS signals over control antibodies used at the same concentration. The enhancement of fluorescence can be explained with the increase of targeting antibodies caused by self-aggregation and lattice formation on the surface of the tumor cells.
Inhibition of Tumor Growth
Antibodies binding to the BCR induce crosslinking of the BCR, which, in turn, inhibits cell proliferation (21) and produces a death signal (22, 23) . Furthermore, chemically dimerized antibodies directed against a B-cell tumor induce hyper-crosslinking of the BCR followed by inhibition of cell division and apoptosis of the tumor (12, 13) . To see if similar enhancement of the antitumor effects of dimerizing antibody were induced by our noncovalent dimerizing T15H-linked antibodies, the two Bcell tumors were cultured in the absence or presence of control and T15H-linked antibodies. As shown in a representative experiment (Fig. 4A) , co-culture of both tumors, 38C13 (Fig. 4A [panel A] ) and Su-DHL4 (Fig. 4A  [panel B] ) with their respective T15H-linked antibodies inhibited the cell growth significantly better compared with the control antibodies.
To test the tumor target specificity of autophilic antibodies in growth inhibition, criss-cross experiments were performed with the 38C13 and Su-DHL-4 cell lines. Inhibition of 38C13 cell growth with S1C5-T15H was statistically greater than mismatched 5D10-T15H (Fig. 4B [panel A]). Similar results on the specificity of autophilic antibodies were obtained with the Su-DHL4 cells (Fig.  4B [panel B] ).
Induction of Apoptosis
As suggested by earlier studies (21-23) , the antitumor effect of antibodies directed against the BCR of B-cell lymphomas in vitro and in vivo might be caused by the induction of apoptosis. Aliquots of tumor cells (38C13 and Su-DHL-4) cultured in the presence of control or T15H-linked antibodies were analyzed for apoptosis using a double stain FACS protocol (16) . The results are summarized in Table 1 . 38C13 and Su-DHL4 cells underwent a moderate amount of apoptosis without antibodies over a 6, respectively 18-hour culture. This apoptosis was enhanced when the respective antibody was added. However, when the T15H-linked antibodies were added, the accumulated number of apoptotic 38C13 cells was almost doubled, and apoptosis of Su-DHL4 cells was more than doubled during the entire culture.
DISCUSSION
The biologic advantage of the autophilic property is exemplified with the S107/T15 antiphosphorylcholine antibody (2) . This self-binding antibody is several times more potent in protecting immune-deficient mice against infection with pneumococci pneumoniae (24,25) than nonself-binding antibodies with the same antigen specificity and affinity.
As shown here, the autophilic antibody function can be transferred to other antibodies by chemically crosslinking a peptide derived from the T15 V H germline sequence. The modified antibody mimics the selfbinding property of the T15/S107 antibody (2), producing a dimeric antibody with increased avidity and enhanced targeting. This approach is an attractive alternative to strategies of improving the targeting of antibodies by either chemical crosslinking or by antibody engineering.
Enhancing the binding of autophilic engineered antibodies to the BCR of B-cell tumor increases the strength of the death signals leading to profound inhibition of cell proliferation in culture. Even though the doubling of apoptosis is demonstrated here, it appears that other mechanisms of growth inhibition are involved.
Crosslinking the BCR of the mature murine B-cell lymphoma A20 can protect against CD95 mediated apoptosis (26) . This antiapoptotic activity of engagement of the BCR by crosslinking antibodies is highly restricted to the time window of CD95 stimulation and is not dependent upon protein synthesis (27) . Our finding that BCR hypercrosslinking per se is pro-apoptotic is not at variance with reports on the antiapoptotic activity of the BCR engagement, because it can be a result of the use of less mature B-cell lines in our study, to different strength of delivered signals by homodimerizing antibodies, or to Fas independent apoptosis (23, 28, 29) .
The use of two BCR idiotope specific antibodies against different tumors offered the opportunity to test the biologic effect of targeting receptors other then the idiotope specific BCR. In criss-cross experiments with autophilic antibodies binding in FACS analysis and inhibition of growth in vitro show a significant enhancement only with the autophilic matched antibody. In this context, it is interesting to speculate whether enhanced tumor targeting would also augment cellular effector functions. Such in vitro and in vivo experiments are in progress.
In an earlier study (13) using chemically homodimer- * 38C13 and Su-DHL4 cells were cultured in absence and presence of 2 g of antibody or antibody peptide conjugate. After a certain time (3 and 6 hours for 38C13; 9 and 18 hours for SU-DHL4) of incubation, the cells were stained with Hochest 342 and MC540 and analyzed by flow cytometry as described (15) .
† Percent of analyzed cells (10,000): R1, cells with 2n DNA that are MC 540 negative; R2, cells with greater than 2n DNA that are MC 540 negative, R3, cells with 2n DNA that are MC 540 bright; R4, cells with greater than 2n DNA that are MC 540 bright; R5, cells displayed reduced Hochest 342 staining and MC 540 bright.
ized antibodies, the Fc domain was not involved in the augmentation of growth inhibition and tumor cells lacking Fc receptors were susceptible to the antigrowth activity of homodimers. Thus, the antitumor effect induced by dimerizing antibodies would not be restricted to tumors expressing Fc-receptors (30, 31) .
The described approach of transferring the naturally occurring autophilic property to other antibodies thereby enhancing their antitumor effect outlines a general method to improve the therapeutic efficacy of antibodies in passive immunotherapy. Such noncovalent antibody complexes offer several advantages over chemically crosslinked antibodies: (i) the equilibrium between monomer and noncovalent homopolymers prevents the formation of precipitating nonphysiologic complexes in solution (this report and [20] ); (ii) autophilic conversion does not compromise the structural integrity of antibodies; and (iii) the method is simple and efficient and does not require a purification step typically needed for chemically crosslinked homodimers that reduces the yield of active Ig dimers. One possible limitation of the approach of using dimerizing antibodies might be the ability to penetrate a large tumor mass. Because the homophilic peptide is of murine origin, it might be immunogenic in humans. Thus, it could be necessary to humanize the murine peptide based on sequence and structural homology using computer modeling. The demonstration that adding a single peptide to the structure of antibodies increases the amount of antibody bound to targets and the antitumor activity encourages attempts to engineer recombinant antibodies expressing the autophilic activity.
